Text Size

Meta-analysis of Efficacy of Topotecan

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01160185
First received: July 8, 2010
Last updated: NA
Last verified: July 2010
History: No changes posted
  Purpose

This meta-analysis was conducted to investigate the efficacy of Topotecan and other treatments for recurrent and stage IVB carcinoma of the cervix


Condition Intervention
Cervical Intraepithelial Neoplasia
 Drug: paclitaxel
Drug: cisplatin
Drug: topotecan

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Survival [ Time Frame: 12 months ]

Enrollment: 1
Study Start Date: June 2009
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
cisplatin Drug: cisplatin
cisplatin monotherapy
Other Name: cisplatin
cisplatin + topotecan Drug: cisplatin
cisplatin monotherapy
Other Name: cisplatin
Drug: topotecan
topotecan
cisplatin + paclitaxel Drug: paclitaxel
paclitacel
Drug: cisplatin
cisplatin monotherapy
Other Name: cisplatin

Detailed Description:

Studies included in the meta-analysis were: GOG-0179, GOG-0204 & GOG-0169

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The search was designed to identify all clinical data published since the Cancer Care Ontario systematic review in 2006. The Cancer Care Ontario systematic review searched MEDLINE (1966 to February 2006), EMBASE (1980 to February 2006), the Cochrane Library (Cochrane Database of Systematic Reviews (2006 Issue 1), and Cochrane Controlled Trials Register (2006 Issue 1)), the Canadian Medical Association Infobase, and the National Guidelines Clearinghouse. The conference proceedings of the American Society of Clinical Oncology (1995-2005) and the European Society of Medical Oncology (2002-2005) were also searched. The search was conducted on 18 December 2008.

Criteria

Inclusion Criteria:

  • Randomised Clinical Trials or systematic reviews or meta-analyses
  • Treatment with topotecan or platinum-based single and combination regimens in female patients of any race with cancer of the cervix recurrent after radiotherapy or stage IVB disease

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01160185

Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT01160185     History of Changes
Other Study ID Numbers: 114015
Study First Received: July 8, 2010
Last Updated: July 8, 2010
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Neoplasms
Cervical Intraepithelial Neoplasia
Carcinoma in Situ
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Cisplatin
Paclitaxel
Topotecan
Antineoplastic Agents
Therapeutic Uses
 Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on June 13, 2013